We appreciate the interest of Kucukseymen in our article. 1, 2 The author suggested that the high incidence of chronic diseases such as diabetes mellitus (DM), hypertension (HT), and obesity, as well as the use of statins, associates with systemic inflammation. Therefore, these factors may affect the results of our study. 2 In our study, 2 the incidence of the chronic diseases mentioned above was almost similar to those in previous studies (about 60%-80%). 3, 4 Although those chronic diseases may lead to high baseline inflammatory cytokine levels and increase cytokine levels after endovascular therapy, it is difficult to adjust for them in patients with peripheral artery disease, which is often accompanied by several atherosclerosis risk factors and diseases in other vascular beds. 5, 6 Among 24 superficial femoral lesions in 18 patients who had follow-up duplex ultrasound sonography in our study, 2 the incidence of HT, DM, obesity, and dyslipidemia tended to be higher but was not significantly different between groups with and without in-stent restenosis (HT: 91.7% vs 100%, P ¼ .423; DM: 58.3 vs 83.3%, P ¼ .289; obesity: 8.3% vs 16.7%, P ¼ .596; dyslipidemia: 58.3% vs 66.7%, P ¼ .732). Furthermore, previous studies have reported that female sex, dialysis, critical limb ischemia, disease severity, and outflow disease have been identified as independent risk factors for in-stent restenosis in femoral artery lesions rather than those chronic diseases. [2] [3] [4] 7 Of course, several limitations (ie, small sample size) must be mentioned in terms of no positive relationship between change of cytokine levels and in-stent restenosis; the impact of baseline chronic diseases on the results of our study, 2 including in-stent restenosis, might be small.
